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AT A GLANCE COMMENTARY
Napole~ao P, et al.
Background
 In a previous study evaluating the influence of
sCD40L in endothelial and vascular function
we found that time changes of sCD40L over
1 month after percutaneous coronary interven-
tion (PCI) stratify STEMI patients;
 Influence of medication, clinical evolution,
biochemical data, and markers of regulation
of endothelial function at genetic and post-
transcriptional levels on sCD40Lwas assessed.
Translational Significance
 For the first time, we found some patients
display low sCD40L concentrations over time
(low-sCD40L group) and others show an in-
crease of sCD40L levels 1 month after PCI
(high-sCD40L group);
 Patients in the low-sCD40L group were associ-
ated to high N-terminal pro-brain natriuretic
peptide and altered expression of 3 micro-
RNAs involved in regulation of endothelial
and cardiac function;
 Low-sCD40L group shows higher frequency
of T allele of G894T polymorphism than in
the high-sCD40L group;
 Low levels of sCD40L 1 month after PCI
distinguish STEMI patients with worse prog-
nosis, a compromised cardiac healing, and a
persistent endothelial dysfunction;
 For STEMI patients, a prognostic value for
sCD40L could be suggested.
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Current opinion suggests a differential role of soluble
CD40 ligand (sCD40L) at different stages of coronary
artery disease (CAD), contrasting with traditional
view of an unvarying function of CD40L/CD40 system
interactions in the disease.1 Cross-sectional studies have
shown circulating levels of sCD40L relate to CAD and
acute manifestations of the disease, such as, acute
myocardial infarction (AMI).2-6 However, an
unequivocal indication of its utility in chronic or acute
CAD manifestations has not been obtained so far.
In the context of CAD, several in vitro studies evi-
denced the relevance of sCD40L in endothelial dysfunc-
tion,7-10 activation of different types of vascular cells,11
leukocyte trafficking, and homing,7,10 among other
distinctive processes of the atherosclerotic pathology.In a previous study conducted by us,5 we have studied
association of sCD40L with markers of endothelial and
vascular function and of platelet activation, after AMI.
On that cohort, evidences were founded of a stratifica-
tion of patients with ST segment elevation myocardial
infarction (STEMI) based on sCD40L concentrations
1 month after percutaneous coronary intervention
(PCI). The present study was designed to identify the
groups of STEMI patients with different profiles of
sCD40L concentrations and verify how medication,
clinical evolution, biochemical data, and markers of
regulation of endothelial function at genetic (endothe-
lial nitric oxide synthase [eNOS] polymorphisms) and
post-transcriptional levels (circulating microRNAs,
which are key regulators of cardiac function12) affect
sCD40L serum levels.MATERIALS AND METHODS
Study groups. A consecutive sample of 200 subjects
(57 women and 143 men) were recruited from the Car-
diology Department and from the outpatient clinic of
cardiovascular risk in Santa Marta Hospital (Centro
Hospitalar de Lisboa Central, Lisbon, Portugal). Among
those, 89 STEMI patients (with documented ST-eleva-
tion changes, creatine kinase .3 times normal and car-
diac troponin .0.01 ng/mL), undergoing PCI as
reperfusion therapy, were enrolled during the first
6 hours of onset of chest pain; and 48 age-matched
patients with stable angina (SA), presenting typical
chest discomfort and/or positive stress tests, which
were submitted to coronary angiography. Furthermore,
63 healthy volunteers, the control group (CTR), with
negative stress test, absence of any history of coronary
disease, life-threatening diseases, or any other disease
or condition that impairs compliance, were also
recruited. These volunteers were not submitted to
coronary angiography.
SA patients and CTR subjects were used as predictors
of altered endothelial regulation in AMI.
Exclusion criteria included age.85 years, significant
comorbidities as peripheral artery disease or carotid ar-
tery disease, known antecedents of malignant, infec-
tious and concurrent inflammatory diseases, chronic
renal insufficiency, and previous myocardial infarction
in the last 5 years.
Laboratory blood analysis for clinical chemistry,
including N-terminal pro-brain natriuretic peptide
(NT-proBNP), C-reactive protein (CRP) and cardiac
troponin T (cTnT), were measured in all patients and
controls (Table I).
Study protocol and follow-up evaluation. STEMI and
SA patients were monitored at 3 time points as follows:
day 0 before PCI and administration of therapy, such as
Table I. Baseline characteristics of patients and controls, expressed as median and interquartile (Q25–Q75),
unless otherwise indicated
CTR (n 5 63) SA (n 5 48) STEMI (n 5 89)
Demographics
Sex (f/m) 23/40 13/35 21/68
Age (y) 55 (47–65) 63 (57–73) 63 (54–72)
Risk factors/comorbidities*
Body mass index (kg/m2) 26 (24–28) 28 (25–29) 27 (24–30)
Waist perimeter (cm) 86 (82–94) 96 (91–102) 99 (89–106)
Smoking, n (%) 4 (6) 4 (8) 39 (44)†‡
Dyslipidemia, n (%) 29 (46) 35 (73)† 47 (53)‡
Hypertension, n (%) 18 (29) 37 (77)† 58 (65)†
Diabetes mellitus, n (%) 2 (3) 16 (33)† 35 (39)†
Previous event medication
No medication, n (%) 46 (73) 5 (10)† 27 (30)†‡
Aspirin, n (%) 4 (6) 32 (67)† 41 (46)†‡
ACE-inhibitor, n (%) 9 (14) 24 (50)† 30 (34)†
b-blockers, n (%) 3 (5) 22 (46)† 26 (29)†‡
Statins, n (%) 10 (16) 37 (77)† 35 (39)†‡
Diagnostic markers
CRP (mg/dL) 3.1 (1.2–3.5) 3.2 (1.6–5.9) 6.30 (3.2–13)
cTnT (ng/mL) ,0.01§ ,0.01§ 0.47 (0.07–3.6)†‡
NT-proBNP (pg/mL) 38 (16–64) 98 (51–247) 356 (145–1577)†‡
eNOS polymorphisms
G894T, GG/T (%) 38/62 37/63 38/63
T786C, TT/C (%) 43/57 50/50 28/72
Abbreviations: ACE-inhibitors, angiotensin-converting enzyme inhibitor; BMI, bodymass index;CRP, C-reactive protein;cTnT, C-reactive protein
and cardiac troponin T; eNOS, endothelial nitric oxide synthase; NT-proBNP; N-terminal pro-brain natriuretic peptide; SA, stable angina.
*Smoking: inhaled use of cigarettes, cigars, or pipes in any quantity, in the year previous to admission; dyslipidemia: total serum cholesterol
$190 mg/dL or serum triglycerides $180 mg/dL or use of lipid-lowering medication; hypertension: systolic blood pressure $140 mm Hg or dia-
stolic, blood pressure $90 mm Hg or use of antihypertensive therapy; diabetes mellitus: fasting plasma glucose concentration $7.0 mmol/L or
2 h plasma, glucose $11.1 mmol/L or confirmed as clinically known and treated diabetes, mellitus.
†P , 0.05 versus CTR group.
‡P , 0.05 versus SA group.
§Values below detection limit.
Translational Research
Volume 176 Napole~ao et al 97antithrombotic agents and IIb/IIIa inhibitors, and 2 and
30 days after PCI. This protocol was designed to eval-
uate AMI patients at acute phase of AMI (rupture and
coronary occlusion) and at the early recovery phase
(cardiac healing and left ventricular remodeling), 2
and 30 days later. All patients were medicated by an
assistance clinician. Previous studies using this cohort
indicated that influence of medication in the values of
inflammatory markers lasted for several days after
PCI.5,13 Therefore, patients’ assessment 1 month after
PCI represents the period of time for medication and
clinical stabilization.
A follow-up was performed by consulting medical re-
cords and/or through telephone contact, for a period up
to 1 year. Evaluated primary end point was cardiovascu-
lar death.
The study was conducted according to principles ex-
pressed in the Declaration of Helsinki and was approved
by the Ethical Committee Board of Centro Hospitalar de
Lisboa Central. All patients and volunteers enrolledsigned a written consent following a full explanation
of the study.
Blood sampling. Blood samples were drawn into
blood collection tubes without additives. For STEMI
and SA patients at the hospital, admission blood was
collected immediately before PCI, which in case of
STEMI patients was performed at hospital admission
(within 6 hours of onset of chest pain). For subsequent
time points and healthy volunteers (CTR), fasting
blood samples were collected early in the morning
to avoid possible circadian variations of measured pa-
rameters.14
Serum was collected after centrifugation (500 g for
10 minutes). Aliquots were stored at 280C until
further analysis (no longer than 6 months). Samples
were thawed only once.
sCD40L measurement. Concentrations of sCD40L
were measured in serum by enzyme-linked
immunosorbent assay commercial kit (R&D Systems).
Each sample was measured in duplicate, and intra-
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,10%. Concentrations were expressed in nanogram
per milliliter.
Having into consideration our previous exploratory
analysis,5 serum was chosen to determine sCD40L by
enzyme-linked immunosorbent assay. In addition, to
safeguard sCD40L stability, temperature was kept at
4C in all steps after blood collection, that is, transport
and processing. A rigorous protocol was applied to miti-
gate source of error originating from pre-analytical and
analytical methodologies.5
DNA extraction and genotyping. Polymorphisms
G894T and T786C of eNOS protein were analyzed.
Genomic DNA was extracted from peripheral blood
cells collected in EDTA tubes using a PureLink
Genomic DNAMini Kit (Invitrogen). A region contain-
ing each polymorphism15 was amplified by polymerase
chain reaction (PCR) using 1 mg of DNA and 1 mM of
specific primers. Amplicons were then digested with
specific restriction enzymes, and the digested
fragments were visualized in a 2% ethidium bromide
agarose gel.
G894T polymorphism corresponds to a modification
in the coding sequence (Glu298/ Asp) located at the
894th position in exon 7 of the eNOS gene, which re-
sults in incorporation of aspartate in place of gluta-
mate.16 T786C polymorphism result in a replacement
of thymine by cytosine at nucleotide-786 position,
decreasing transcription of eNOS gene and reducing
in half the promoter activity.15
MicroRNA quantification analysis. RNA was extracted
from serum samples using miRCURY RNA Isolation
Kit (Exiqon). Complementary DNA was synthesized
from RNA using Universal cDNA synthesis kit
(Exiqon).
A microarray screening of circulating microRNAs
was performed by quantitative PCR using a panel of
179 microRNAs (miRCURY LNAUniversal RT micro-
RNA PCR assays; Exiqon). Based on those results, 19
microRNAs were preselected, namely, miR-1, miR-
15b, miR-19b, miR-20b, miR-21, miR-27b, miR-32,
miR-99a, miR-125b, miR-126, miR-133a, miR-145,
miR-146, miR-147a, miR-155, miR-208b, miR-222,
miR-382, and miR-485.
Expression of preselected microRNAs (LNA PCR
primer, Exiqon) was assessed. Amplification was per-
formed by quantitative real-time PCR followed by
determination of melting curve according to the condi-
tions as follows: 95C for 10 minutes followed by 45 cy-
cles of 95C for 10 seconds and 60C for 60 seconds.
Triplicates were performed. Raw Ct values were
normalized by global normalization method in each
sample, and expression levels of all microRNAs calcu-
lated by the Delta-Delta-Ct method as implemented inDataAssist v2 software. Fold changes .2 were
considered significant. Results are expressed in relative
quantification, which shows fold changes of a specific
microRNA in 2 populations.17 Comparisons were as fol-
lows: CTR versus low-sCD40L group; CTR versus
high-sCD40L group; low-sCD40L versus high-
sCD40L group; CTR versus SA; low-sCD40L group
versus SA; and high-sCD40L group versus SA. For
STEMI and SA patients, values were compared at hos-
pital admission and 30 days later. A relative quantifica-
tion value different than 1 indicates different
expressions of a specific microRNA in 2 populations.17
Statistical analysis. Data were summarized as median
and interquartiles (IQ) 25% and 75% (Q25–Q75) for
continuous variables and as proportions for categorical
variables. Noncontinuous variables were analyzed us-
ing a 2 3 2 table and Fisher exact test and using a gen-
eral linear model analysis of variance with Bonferroni
correction for continuous variables.
As measures of blood markers for each STEMI and
SA patient were not independent over time, a linear
mixed effects (LME) model was applied. This statistical
model describes longitudinal variations of each patient
allowing to estimate differences in average slopes be-
tween baseline (hospital admission, day 0) and other
time points, giving a measure of the variation of each
blood marker over time. To apply LME, a logarithm
transformation was applied to sCD40L.
LME model was also used to compare longitudinal
variation between groups of patients (SA, STEMI and
sCD40L-based STEMI groups and SA), and assess cor-
relations between sCD40L concentrations over time and
other blood markers, demographics, clinical parame-
ters, and therapy.
Values of P , 0.05 were considered statistically sig-
nificant. Calculations were performed using SPSS
(version 22.0) and R (version 2.11.1) software.
RESULTS
STEMI patients’ stratification based on sCD40L levels
measured 30 days after PCI. Soluble sCD40L concentra-
tions were reduced at baseline in STEMI and SA
patients when compared with CTR. One month after
PCI, sCD40L levels increased in SA patients to values
similar to CTR, whereas in STEMI patients, they re-
mained significantly diminished (Fig 1, A). These
changes of sCD40L concentrations over time were
significant in both STEMI and SA as previously
reported by us.5
Two groups of patients were identified based on the
50% percentile of sCD40L concentrations measured 1
month after PCI (cutoff concentration of 2.26 ng/mL).
The low-sCD40L group describes cases with sCD40L
concentrations below the 50% percentile (median; IQ;
Fig 1. Variations of sCD40L levels over 1 mo after PCI in studied populations (CTR group, SA and STEMI pa-
tients, A) and in STEMI groups, low- and high-sCD40L, based on sCD40L concentrations measured 1 mo after
PCI (B). Significances (P, 0.05) versus CTR (*) and versus low-sCD40L group (**) in each evaluation time point
are indicated. PCI, percutaneous coronary intervention; SA, stable angina.
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mL), whereas the high-sCD40L group describes cases
with sCD40L levels above the 50% percentile (median;
IQ; minimum–maximum: 3.48; 3.00–5.66; 2.33–
11.2 ng/mL). Soluble CD40L concentrations in high-
sCD40L group of STEMI patients were similar to
sCD40L levels of CTR and of SA patients at day 30.
Modeling sCD40L average changes over time in
these 2 groups of STEMI patients, a significant differ-
ence in longitudinal profile was observed (F 5 8.54,
P , 0.0001) as can be inferred in Fig 1, B. Progressive
average increase in sCD40L levels from hospital admis-
sion until day 30 in the high-sCD40L group contrasts
with the average decrease in sCD40L after AMI in the
low-sCD40L group.
High- and low-sCD40L groups did not differ in terms
of number of patients, demographics, risk factors, and
comorbidities (Table II). Influence of medication was
addressed previously5 in this cohort, and no significant
correlations between medication intake (pre-event and
after hospital discharge) with sCD40L levels in serum
were verified. As described in Table II, the 2 groups
of STEMI patients revealed similar prescriptions; there-
fore, medicines do not contribute to stratification.
A 1-year clinical follow-up was considered having
cardiovascular death as primary end point. In the overall
of STEMI patients assessed, 5 patients died of cardio-
vascular causes (mean survival time of 4 months). Three
of these patients died ,1 month after PCI; conse-quently, they cannot account for sCD40L stratification.
However, on those patients, sCD40L concentrations at
day 2 (0.77, 0.68–1.02) were similar to those of the
low-sCD40L group (Fig 1). Furthermore, the remaining
2 deaths (1 year after PCI) correspond to patients who
were classified in the low-sCD40L group.
Longitudinal changes of NT-proBNP differed in sCD40L-
based STEMI groups. NT-proBNP showed significant
changes in the 2 groups of STEMI patients (Table III).
NT-proBNP concentrations 2 and 30 days after PCI
significantly differ in both groups (P , 0.05).
Concentrations of this natriuretic peptide remain high
over 30 days in the low-sCD40L group contrasting
with those in the high-sCD40L group, where levels
sharply decrease to day 30. Consequently, NT-proBNP
time-variation trend over 30 days significantly differed
in the low- and high-sCD40L groups (F 5 6.54,
P 5 0.015). In addition, in STEMI patients, sCD40L
increases were correlated with decreases in
NT-proBNP concentrations.
eNOS genotypes in sCD40L-based STEMI
groups. Frequency of polymorphisms of eNOS differed
in the 2 sCD40L groups of STEMI patients (Fig 2).
Regarding G894T polymorphism, T allele was more
frequent in the low-sCD40L group (82%) in
comparison with that in the high-sCD40L group (33%,
P , 0.05). Frequency of T allele in the CTR group was
diverse (Table I). No remarkable differences in
frequency of eNOS T786C polymorphism were
Table III. Concentrations of CRP, cTnT, and NT-
proBNP measured at 3 time points (hospital
admission—days 0, 2, and 30 after PCI) in low- and
high-sCD40L groups of STEMI patients
CRP (mg/dL) cTnT (ng/mL) NT-proBNP (pg/mL)
Low-sCD40L
Day 0 4.3 (3.2–7.4) 0.85 (0.07–2.9) 356 (158–1506)
Day 2 36 (15–47) 2.7 (1.9–4.0) 1567 (851–3125)
Day 30 3.6 (3.2–7.2) ,0.01* 1090 (625–2257)
High-sCD40L
Day 0 5.2 (3.2–9.3) 0.24 (0.06–3.5) 175 (80–1063)
Day 2 21 (11–33) 2.2 (1.7–3.1) 628 (369–1423)†
Day 30 3.2 (1.7–5.3) ,0.01* 396 (301–707)†
Abbreviations: CRP, C-reactive protein; cTnT, C-reactive protein
and cardiac troponin T;NT-proBNP, N-terminal pro-brain natriuretic
peptide; PCI, percutaneous coronary intervention.
Values are median and interquartiles (Q25–Q75).
*Below detection limit.
†Significantly different from the low-sCD40L group, P , 0.05.
Table II. Characteristics of low- and high-sCD40L
groups of STEMI patients
Low-sCD40L
(n 5 26)
High-sCD40L
(n 5 25)
Sex (f/m) 5/15 2/18
Age (y) 62 (56–75) 56 (48–68)
BMI (kg/m2) 27 (24–31) 28 (25–31)
Waist perimeter (cm) 98 (82–112) 100 (94–105)
Risk factors/comorbidities
Smoking 10 (38) 12 (48)
Dyslipidemia 16 (62) 17 (68)
Hypertension 17 (65) 20 (80)
Diabetes mellitus 7 (27) 14 (52)
Medication—pre-event
No medication, n (%) 19 (73) 19 (76)
Aspirin, n (%) 19 (35) 13 (52)
ACE-inhibitor, n (%) 15 (58) 8 (32)
Anti-platelet inhibitors, n (%) 6 (23) 9 (36)
b-blockers, n (%) 6 (23) 11 (44)
Statins, n (%) 9 (35) 14 (56)
Medication—discharge
Aspirin, n (%) 22 (85) 25 (100)
ACE-inhibitor, n (%) 18 (69) 22 (88)
Anti-platelet inhibitors, n (%) 124 (92) 25 (100)
b-blockers, n (%) 17 (65) 20 (80)
Statins, n (%) 22 (85) 25 (100)
Abbreviations: ACE-inhibitors, angiotensin-converting enzyme in-
hibitor; BMI, body mass index.
Values are medians and interquartiles (Q25–Q75), unless indi-
cated.
Translational Research
100 Napole~ao et al October 2016observed in both sCD40L-based STEMI groups and
CTR.
MicroRNAs profiles in the sCD40L-based STEMI
groups. MicroRNA quantification of 19 preselected
microRNAs was performed in all samples of CTR,
SA, and STEMI patients at days 0 and 30. Differences
were found for miR-19b, miR-145, and miR-222
(Fig 3).
At hospital admission, STEMI patients did not show
atypical microRNAs expression profile compared with
that of the CTR group. However, 1 month after PCI, pa-
tients in sCD40L groups exhibited distinct microRNAs
expression. No differences were verified in none of the
19 microRNAs quantified in the high-sCD40L group at
day 30 versus CTR or SA. However, in the low-sCD40L
group, miR-19b expression was 3-fold higher compared
with that in CTR (Fig 3, A). Furthermore, at day 30,
expression of miR-19b and miR-222 was both 4-fold
higher in the low-sCD40L group comparing with SA
patients (Fig 3, A and C).
When low- and high-sCD40L groups were compared,
striking differences in microRNA profile involving
expression of miR-19b, miR-145, and miR-222 were
observed (Fig 3). At day 30, expression of miR-19b,
miR-145, and miR-222 in the low-sCD40L group was4.5–6-fold increased comparing with the high-
sCD40L group (Fig 3).
Therefore, the low-sCD40L group was consistently
associated with an altered post-transcriptional profile
of microRNAs, whereas the high-sCD40L group
showed similarities with CTR and SA.
DISCUSSION
This work showed sCD40L changes after PCI stratify
STEMI patients, and these changes were associated
with genetic and post-transcriptional markers. Results
shown sCD40L concentrations 1 month after PCI
stratify patients in 2 groups as follows: (1) a group of
patients showing persistently low sCD40L concentra-
tions over time (low-sCD40L group) and (2) a group
of patients where sCD40L levels progressively increase
to day 30 (high-sCD40L group).
Drug intake and clinical characteristics add no
explanation to the stratification of STEMI patients.
Nevertheless, in the low-sCD40L group, low sCD40L
levels were linked to high concentrations of
NT-proBNP, higher frequency of eNOS polymorphism
G894T, and altered expression of microRNAs. This pro-
file clearly departs from the high-sCD40L group, which
shares similarities with CTR for sCD40L concentra-
tions and microRNAs profile. The high-sCD40L group
also showed comparable sCD40L longitudinal profile
with SA patients 1 month after PCI.
Stratification of CAD patients based on sCD40L
levels was previously proposed.4,18,19 Increased
sCD40L levels have been used to identify patients
with unstable CAD or at risk for acute syndromes,
independently of other predictive variables.6,18,20
Apart from important methodology issues previously
Fig 2. Variations of genotyping polymorphisms of eNOS T786C and G894T in low- and high-sCD40L groups of
STEMI patients.
Fig 3. MicroRNAs miR-19b (A), miR-145 (B) and miR-222 (C) serum levels in CTR and SA groups and in
sCD40L-based STEMI groups. Values represented are RQ values versus CTR group (reference group).
*P , 0.05 versus CTR, dP , 0.05 versus SA group at day 30, 4P , 0.05 versus low-sCD40L group at day 30.
RQ, relative quantification; SA, stable angina.
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sessed STEMI patients or variations of sCD40L over
time as in the current work. Furthermore, more recent
studies not only fail to demonstrate an association of
high level of sCD40L with increased risk of cardiovas-cular events,21-24 but in fact, indicate an inverse relation
of sCD40L levels with risk of recurrent ischemia.23
The CD40/CD40L system represents a major co-
stimulator system triggering different signaling path-
ways mainly attending as amplification of immune
Translational Research
102 Napole~ao et al October 2016and inflammatory responses,25 including in endothelial
cells.26,27 Therefore, CD40L can be implicated in
promoting inflammation,9 angiogenesis,28 and endothe-
lial dysfunction.7,29 Furthermore, overexpression of
CD40 and CD40L was demonstrated in hearts of mice
with myocarditis providing a mechanistic link
between damagedmyocardium and immune response.30
Soluble CD40L form also plays a role in CD40/
CD40L interaction between immune cells and nonim-
mune cells in a much wider context of the disease
than thrombosis.5,31 Increases in solubilized CD40L
may indicate lesser interaction with membrane-bound
CD40 in target cells, either by release of CD40L
exposed on cell surface or decreased expression of
CD40L due to lack of extracellular and intracellular
inhibitory stimulus of integrins and inflammatory
molecules,31 rather than representing an increased co-
stimulatory possibility. In fact, high affinity of
sCD40L for CD40 when tumor necrosis factor alpha re-
ceptors and integrins are expressed was reported.32,33
This hypothesis finds an echo in the results obtained
in our study, suggesting a detrimental effect of low
sCD40L in AMI patients.
To our knowledge, this is the first clinical study
directly linking sCD40L changes in the AMI evolution
with post-transcriptional microRNAs profile. Previous
in vitro and animal studies establish several microRNAs
as having post-transcriptional regulator function of
several pathways implicated in AMI.34,35 Among
those are some microRNAs identified in the present
study as upregulated in the low-sCD40L group versus
controls such as miR-145. Previous studies positively
related miR-145 to troponin T release establishing
involvement of this microRNA in neointima repair in
response to vascular injury. Thus, elevated miR-145
levels in the low-sCD40L group might be a result of
vessel and myocardial injury as a consequence of MI.
The miR-19b and miR-222 had also been related to
endothelial and vascular dysfunction.36,37 MiR-222
has also been associated with vascular wound healing
after injury and myocardium function and could
contribute to heart diseases such as hypertrophic cardio-
myopathy.37 Taking together, there seems to exist a pro-
file of microRNAs related to endothelial dysfunction,
compromised cardiac function, and myocardium hyper-
trophy associated with the low-sCD40L group, which is
clearly different from controls, SA patients, and the
high-sCD40L group.
Moreover, the low sCD40L group showed a higher
frequency of T allele of G894T eNOS polymorphism.
Prevalence of G894T eNOS polymorphism has been
associatedwith physiological alterations andworse clin-
ical outcomes, for example, low plasma NO concentra-
tions and risk of CAD development.16,38 Thispolymorphism leads to a conservative replacement of
glutamate with aspartate causing conformational
alterations.39 Consequently, eNOS susceptibility to pro-
teolytic cleavage in endothelial cells and vascular tissues
is higher, which has a functional effect on the enzyme,39
and subsequently on NO bioactivity.39,40 Antoniades
et al40 report that, in humans, G894T polymorphism
may modify eNOS activity and is associated with endo-
thelial dysfunction by decreasing NO but only under
endothelial cell stimulation. According to those authors,
the G894T polymorphism has no effect on the control
group.40 These previous results suggest heterozygosity
for the T allele could be associated with a compromised
endothelial function in low-sCD40L STEMI patients,
but not in the healthy subjects (CTR).
Finally, in our study, STEMI patients in the low-
sCD40L group had higher NT-proBNP values, which
are associated with adverse outcomes41-43 and is a
clinically relevant marker of left ventricular
dysfunction.44 Therefore, lower sCD40L concentrations
can be associated with worse outcome and left ventric-
ular dysfunction, as far as NT-proBNP variations are
concerned.
In conclusion, our study shows STEMI patients with
lower sCD40L levels have worse prognosis, a compro-
mised myocardium function recovery, and a persistent
endothelial dysfunction, as given by relationship be-
tween sCD40L, NT-proBNP, specific profile of micro-
RNA expression, and frequency of G894T eNOS
polymorphism. Results point out to involvement of
sCD40L not only in thrombosis and inflammation but
also in other important processes in cardiac, endothelial
cells, and vascular system dysfunction, as we reported
previously.5 This hypothesis could explain why the
sCD40L-based stratification of STEMI patients was
observed 1 month after PCI, in a period when the throm-
botic effect is already diminished.
We hypothesize that in STEMI patients low
sCD40L levels reflect a compromised recovery capac-
ity of myocardium after infarct and persistent endo-
thelial dysfunction. However, further mechanistic
studies are mandatory to understand the molecular
pathways involved in sCD40L-associated cardiac
healing. Nevertheless, sCD40L could have a prog-
nostic value in STEMI patients as a new biomarker
of both endothelial and vascular function, being able
to identify patients with higher risk of compromised
cardiac healing.ACKNOWLEDGMENTS
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